Based on these results, elacestrant has recently been approved by the FDA for use in post-menopausal women or adult men whose disease progressed after at least one line of ET and who had ER-positive, HER2-negative, ESR1-mutated advanced or metastatic BC. The gene discussed is ERBB2; the disease is breast cancer.